Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity

Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson's disease and Alpha-1 antitrypsin (A1AT) deficiency, announced the closing of a US $32 million financing round.

The round included participation from all existing investors including: Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital's Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria.

"This financing enables us to generate the first clinical proof of concept data with our corrector for MC4R-d driven obesity, a serious and debilitating condition without current treatment options," commented Dr. Clarissa Desjardins, CEO of Congruence. "We will also advance our programs in GBA-1 Parkinson's Disease and Alpha-1 Antitrypsin Deficiency toward Development Candidate nomination this year."

Congruence plans to start a Phase 1 trial of CGX-926 in healthy volunteers, including a Phase 1b efficacy cohort in MC4R-d patients, in early 2026. Congruence will also advance its programs targeting Parkinson's Disease and A1AT-deficiency into late preclinical testing.

"Congruence is building a transformative pipeline of drugs it has discovered leveraging its powerful computational engine, Revenir™. The team has demonstrated scientific rigor and capital efficiency in advancing these important medicines into late preclinical testing," commented Daniel Hétu, M.D., MBA, Managing Director at Lumira Ventures. "We are proud to continue to support Congruence as it advances its lead program CGX-926 into clinical testing and inches closer towards its mission of treating diseases of high unmet medical need."